KZIAKAZIA THERAPEUTICS LTD

Nasdaq kaziatherapeutics.com


$ 0.37 $ 0.00 (0.03 %)    

Wednesday, 11-Sep-2024 15:56:01 EDT
QQQ $ 468.28 $ 9.96 (2.17 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 0.3657
$ 0.37 x 100
-- x --
-- - --
$ 0.19 - $ 1.58
245,450
na
8.34M
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-07-2006 11-06-2006 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-kazia-therapeutics-maintains-2-price-target

HC Wainwright & Co. analyst Sean Lee reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $2 price target.

 whats-going-on-with-kazia-therapeutics-shares-thursday

Kazia Therapeutics announced results from its Phase II/III trial in regards to the treatment of glioblastoma, a type of brain c...

 kazia-therapeutics-shares-are-jumping-today-successful-study-for-brain-cancer-treatment

Kazia Therapeutics reports a 33% improvement in overall survival for newly diagnosed glioblastoma patients using paxalisib in a...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION